1. What's on the Horizon? Assessing New First-Line Paradigms for AML Patients Ineligible for Intensive Chemotherapy

3. Treatment Options for AML Patients Ineligible for Intensive CT

4. NCCN Clinical Practice Guidelines: AML

5. AML Patients Ineligible for Intensive CT: Challenges of Traditional Therapy

6. Venetoclax Mechanism of Action

7. Availability of Venetoclax

8. Venetoclax + HMAs in Elderly Patients With Untreated AML: Study Design

9. Venetoclax + HMAs in Elderly Patients With Untreated AML: Responses

10. Venetoclax + HMAs in Elderly Patients With Untreated AML: Serious AEs

11. Assessing Fitness and Making Treatment Decisions

12. Phase 1/2 Study of Venetoclax with LDAC in Treatment-Naive, Elderly Patients with AML Unfit for Intensive CT: 1-Year Outcomes

13. Phase 1/2 Study of Venetoclax with Low-Dose Cytarabine in Treatment-Naive, Elderly Patients with AML Unfit for Intensive CT: 1-Year Outcomes (cont)

14. Glasdegib + LDAC vs AZA or DEC Among AML Patients Ineligible to Receive Intensive CT

15. Glasdegib Mechanism of Action

16. Glasdegib + LDAC vs AZA or DEC Among AML Patients Ineligible to Receive Intensive CT: CR Results

17. Glasdegib: Potential Role in AML Treatment

18. Resurgence of Nontargeted Therapy for AML Treatment

19. Gemtuzumab Ozogamicin vs BSC In Older Patients With AML Unsuitable for Intensive CT: EORTC-GIMEMA AML-19 Trial

20. Gemtuzumab Ozogamicin vs BSC In Older Patients With AML Unsuitable for Intensive CT: EORTC-GIMEMA AML-19 Trial

21. Gemtuzumab Ozogamicin: Potential Role in AML Treatment

22. IDH Inhibitors In AML

23. Availability of IDH Inhibitors

24. Ivosidenib In Patients with IDH1-Mutant Untreated AML: Results From a Phase 1 Dose Escalation and Expansion Study

25. Unanswered Questions for Treating AML Patients Ineligible for Intensive CT

26. Venetoclax + HMAs in Elderly Patients With Untreated AML: Responses

27. FLT3 Inhibitors In AML

28. Phase 3 Study of Quizartinib vs SOC in FLT3-ITD R-R AML: QUANTUM-R

29. Gilteritinib In Newly Diagnosed FLT3 Mutated AML Patients Ineligible for Intensive Induction CT: Data From Safety Cohort

30. Mutational Co-Occurrence in AML

31. FLT3 Inhibitors: Potential Role in AML Treatment

32. Fit vs Unfit: How Do You Decide?

33. Need For Assessments of Fitness In the Future?

34. Evaluating MRD In AML

35. High MRD-Negative Rates Seen with Venetoclax in Patients With AML

36. Conclusions

37. Abbreviations

38. Abbreviations (cont)

39. Abbreviations (cont)